SANAHealthcare · BiotechnologyThe 9 Wall Street analysts covering Sana Biotechnology, Inc. hold a median 12-month price target of $7 — +97.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Sana Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (21): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SANA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +97.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | B of A Securities | Maintains | Buy | $7.00 → $6.00 |
| 14 Apr 2026 | Wedbush | Maintains | Outperform | $6.00 → $7.00 |
| 14 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Jan 2026 | B of A Securities | Maintains | Buy | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | Wedbush | Maintains | Outperform | — |
| 30 Oct 2025 | Citizens | Maintains | Market Outperform | — |
| 24 Sept 2025 | Wedbush | Initiates | Outperform | — |
| 3 July 2025 | Morgan Stanley | Assumes | Overweight | $12 |
| 24 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 24 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | Citizens Capital Markets | Upgrade | Market Outperform | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Mar 2025 | Jefferies | Initiates | Buy | — |
| 8 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Jan 2025 | TD Cowen | Upgrade | Buy | — |
| 27 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SANA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 13% of US stocks
Cheaper than 79% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sana Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A law firm is contacting Sana Biotechnology shareholders regarding potential breaches of fiduciary duties by company insiders, offering to handle matters on a contingent fee basis.
Why it matters — This alerts SANA watchers to possible legal challenges against the company's leadership that could impact governance and shareholder value.
The 9 Wall Street analysts covering Sana Biotechnology, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Sana Biotechnology, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sana Biotechnology, Inc. 32 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Sana Biotechnology, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +97.2% from the last close, and Ticker Nerd's factor model ranks Sana Biotechnology, Inc. 32 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sana Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SANA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $12 over the next 12 months.
Sana Biotechnology, Inc. returned +3.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing engineered cell therapies to repair and control genes in cells or replace missing or damaged cells, addressing the underlying causes of diseases.
The most recent item we track (PRNewsWire, 29 July 2026): "Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?". A law firm is contacting Sana Biotechnology shareholders regarding potential breaches of fiduciary duties by company insiders, offering to handle matters on a contingent fee basis.
Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing engineered cell therapies to repair and control genes in cells or replace missing or damaged cells, addressing the underlying causes of diseases. The company focuses on two primary platforms: hypoimmune technology, which modifies cells to evade immune rejection for off-the-shelf allogeneic therapies, and in vivo cell engineering using fusogen delivery systems to precisely target and edit genes within patients' bodies. These platforms target oncology with CAR-T programs for B-cell cancers, autoimmune disorders, and type 1 diabetes through beta cell replacement, among other areas. Sana Biotechnology, Inc. emphasizes scalable manufacturing to reduce costs and improve patient access, integrating expertise in stem cell biology, immunology, gene editing, and therapeutics development. Founded in 2018 and headquartered in Seattle, Washington, the company advances a pipeline of innovative candidates designed to transform treatment outcomes in genetic and acquired diseases by overcoming key biological barriers like immune response and delivery challenges.
CEO Dr. Steven D. Harr M.D. · 142 employees · United States · https://www.sana.com